24
ALL1
GenVivo5
Rznomics18
Viracta TherapeuticsYear
24
ALL7
20247
20233
20222
20215
2020DEALS // DEV.
24
ALL4
Deals20
DevelopmentsCountry
24
ALL5
SOUTH KOREA19
U.S.A24
ALL1
BVF Partners L.P.1
Charles River20
Inapplicable2
Sunesis PharmaceuticalsTherapeutic Area
24
ALL24
OncologyStudy Phase
24
ALL15
Phase II7
Phase I/ Phase II1
Phase I1
PreclinicalDeal Type
24
ALL20
Inapplicable2
Merger1
Partnership1
Private PlacementProduct Type
24
ALL6
Cell and Gene therapy18
Other Small MoleculeDosage Form
24
ALL3
Intramuscular Injection1
Intratumoral Injection3
Oral10
Oral Capsule5
Oral Tablet2
UndisclosedLead Product
24
ALL1
GVO-110218
Nanatinostat5
RZ-001Target
24
ALL18
HDAC1
Undisclosed5
hTERT expressionLead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Therapeutics Announces NAVAL-1 Trial Closure and Strategic Alternatives
Details : Viracta's lead program, Nana-Val evaluates the all-oral combination of nanatinostat & valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Product Name : Nana-Val
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 26, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Secures Expanded Access for Glioblastoma Patients with Novel Therapy
Details : RZ-001 is an anti-HCC activity by suppressing hTERT expression selectively in cancer cells. It is being in combination With valganciclovir for the treatment in 18 and older with Glioblastoma.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 25, 2024
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Announces Positive Data from NAVAL-1 Trial and Updated Nana-val Development Plan
Details : Viracta's lead program, Nana-Val evaluates the all-oral combination of nanatinostat & valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Product Name : Nana-val
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 14, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : GVO-1102,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
GenVivo Begins Patient Dosing in Phase I/Ib Trial for GEN2 Gene Vector Immunotherapy
Details : GEN2’s dose-escalation trial, GVO-1102 non-replicating immunotherapy vector administered by intravenous infusion with valganciclovir for the treatment of patients suffering from neoplasms.
Product Name : GVO-1102
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 27, 2024
Lead Product(s) : GVO-1102,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Reports Positive Results in NAVAL-1 Trial for EBV+ Lymphoma
Details : Viracta’s lead program VRx-3996 combines nanatinostat and valganciclovir in a Phase 2 trial for EBV-positive relapsed/refractory lymphoma, aiming to address unmet patient needs.
Product Name : Nana-val
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Completes Enrollment in NAVAL-1 Trial for Peripheral T-Cell Lymphoma
Details : Nana-val (nanatinostat with valganciclovir) is an all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for EBV+ peripheral T-cell lymphoma.
Product Name : Nana-val
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Secures Orphan Drug Designation for RZ-001 in Hepatocellular Carcinoma
Details : RZ-001, which selectively suppresses hTERT expression in cancer cells, is under Phase 1/2 clinical trials combined with valganciclovir for hepatocellular carcinoma.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 02, 2024
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of EBV-related nasopharyngeal carcinoma.
Product Name : Nana-val
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Rznomics Inc. Secures Fast Track Designation from the U.S. FDA for RZ-001
Details : RZ-001, the RNA replacement enzyme-based cancer gene therapy for the treatment of GBM, targets and cleaves hTERT mRNA and replaces the mRNA with the therapeutic gene RNA.
Product Name : RZ-001
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : RZ-001,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoforms, which induces viral genes that are epigenetically silenced in EBV associated malignancies. It is currently being investigated in combination ...
Product Name : Nana-val
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable